Veradermics, Incorporated is expected to report zero revenue and a consensus EPS loss of -$0.63 for Q2 2026, with the stock currently trading at $114.39 against a bullish average analyst price target of $163.50.
Investors are primarily focused on clinical pipeline updates for VDPHL01, a first-in-class non-hormonal oral therapy for pattern hair loss that is currently progressing toward a planned 2027 FDA submission.
The report follows a period of heightened volatility triggered by the August 2 IPO lockup expiration, which has pressured shares despite robust Phase 3 data and strong institutional backing from firms like Fidelity.
Management is expected to provide critical updates on the company's cash runway, with current estimates suggesting over $390 million in reserves to fund operations through upcoming Phase 3 readouts.